Alternative Funding Sources for Life Sciences Companies
An In-Depth Look At Public Company Follow-Ons, Converts and PIPEs and Non-Traditional Capital Sources for Private Companies

While VC financings and traditional IPOs grab the headlines in life sciences, companies in this space are always looking for new ways to raise capital. An increasing number of biotech startups are going public through reverse mergers, while companies who are already public are doing secondary offerings, convert offerings and private placements to sustain their product development and to finance acquisitions. Before going public, privately held companies are likewise looking for alternative funding sources to supplement VC money. An informed panel of life science executives, venture capitalists, bankers and attorneys will survey the landscape for these alternative ways to raise capital.

Thursday, May 19, 2005
8:30 – 11:00 am

America North Ballroom
Westin Copley Place
10 Huntington Ave. Boston, MA

Registration

Speakers:

Keynote Thomas M. Finneran President, Massachusetts Biotechnology Council Bio

James M. Frates, Vice President, CFO and Treasurer, Alkermes, Inc.

Andrew L. Salzman, M.D., President and CEO, Inotek Pharmaceuticals Corporation

Jessica Chutter, Managing Director, Morgan Stanley

Mitchell S. Bloom, Partner, Goodwin Procter LLP

Ellen S. Baron, PhD., Investment Manager, Oxford Bioscience Partners